Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program [abstract 37].

Welzel TM, Zeuzem S, Petersen J, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program [abstract 37]. In Presented at the Liver Meeting 2016. San Francisco, CA; 2016.

Publication Type:

Conference Paper

Authors:

T M Welzel; Stefan Zeuzem; Petersen, J.; et, al

Source:

Presented at the Liver Meeting 2016, San Francisco, CA (2016)

Cited On:

Export Citation:
RIS Format
Top